Before you read on, please be aware that the analysis below is my opinion only and may include flawed assumptions and inaccuracy of logic; therefore, caveat emptor applies here. Furthermore, all emphasis (color-coded, boldness, and underlined) on the excerpts are my own.
This is one tough, resilient bull! Just by looking at the uptrend ever since its ugly drop in the 3rd quarter of 2018, I say it is going to make a new high soon. Unless the “sell in May and go away” becomes a true prophecy for 2019, this bull is still going strong at the moment.
I didn’t do much this week except to close my $CARA call options position to lock in my gain after the price went up the first two days of the week and took a dive on Thursday that took out the Monday low. I closed my position on Friday morning when it failed to bounce. I may buy back my call options when $CARA drops back to support between $17 and $18 areas.
$IBIO – This baby fell below 80 cents this week, and I took the opportunity to add some more. The way I see it, as more and more biosimilars are approved by FDA, the advent of low-cost biosimilars made possible by plant-based technology to substitute the more expensive biologic drugs that are going off-patent becomes even more critical. This is especially important for countries such as China, Brazil, South Africa, and around the globe outside the U.S. In my opinion, it is a matter of “when,” not “if.”
$LRAD – This one can see a big jump if the company can win a country-wide contract for their superior mass-notification systems. I’m going to sit tight and wait for it.
Due to downdraft from $LRAD, my port gave back a bit this week.
Current positions (in alphabet order):
Stocks = IBIO LRAD
Call options = TRXC
Up 24.2% YTD
My 2 cents
From my camera: